The French company Diabeloop announced on 1 March 2021 that it has integrated the Accu-Chek Insight insulin pump from Roche into its DBLG1 System. The automated and personalized solution for Type 1 diabetes management will be available in select European countries in early 2021.
DBLG1 System, the AID (Automated Insulin Delivery) system from Diabeloop individualizes treatment by automating insulin decisions. It connects a CGM (Continuous Glucose Monitoring), an insulin pump and Diabeloop’s self-learning algorithm hosted in a dedicated handset to function as a hybrid-closed loop. The algorithm analyses data in real time and takes into account the physiology, history and data entries (meals or exercise) to determine either to maintain current settings, adjust or even stop basal insulin delivery to avoid a predicted low/high or deliver a bolus to correct a high.
With the integration of the Accu-Chek Insight insulin pump, Diabeloop and Roche offer people with diabetes the possibility to choose an automated and personalized management using a sleek-designed and pre-filled insulin cartridge pump.
Erik Huneker, founder and CEO of Diabeloop commented, “Diabeloop’s long standing mission is to relieve people with diabetes of their constant day and night burden and offer them more personalized solutions. Combining our self-learning algorithm with the reliability and accuracy of the Accu-Chek Insight insulin pump allows Diabeloop and Roche to propose a safe, easy-to-use and individualized treatment management solution, so that people with diabetes can live their life without interruption.”
Meanwhile Marcel Gmuender, Head of Roche Diabetes Care, added, “Automated insulin delivery is a big step towards true relief for people with diabetes. The Accu-Chek Insight insulin pump will be the first pump with a pre-filled cartridge that can be operated in hybrid-closed loop mode. Together with Diabeloop, we strive to bring a unique, holistic approach of automated insulin delivery to people with Type 1 diabetes supporting their self-management of constantly adjusting their insulin dose and thus enabling them to manage their condition more easily in everyday life.“
A European roll-out is expected to begin sometime in 2021.
To read more about Diabeloop, see our feature on p.34 of our January 2021 issue.